RIPK3 and cardiac hypertrophy: By WGA staining, it was observed that in the cross-sectional area of mouse cardiomyocytes the IVS and LVPW of each myocardial hypertrophy mouse group were significantly increased (P < 0.05), compared with WT (AMP-AngII)+NS group given RIPK3 inhibitor GSK'872 (Figures 7(c) and 7(d)).